NovoCure Limited (NVCR)

Last Price:  

Company Description

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $494.37M
Net Income (Most Recent Fiscal Year) $19.81M
PE Ratio (Current Year Earnings Estimate) 606.00
PE Ratio (Trailing 12 Months) 680.42
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 26.78
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 27.62
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) 408.48
Pre-Tax Margin (Trailing 12 Months) 3.66%
Net Margin (Trailing 12 Months) 4.01%
Return on Equity (Trailing 12 Months) 6.13%
Return on Assets (Trailing 12 Months) 3.15%
Current Ratio (Most Recent Fiscal Quarter) 8.80
Quick Ratio (Most Recent Fiscal Quarter) 8.56
Debt to Common Equity (Most Recent Fiscal Quarter) 0.90
Inventory Turnover (Trailing 12 Months) 4.15
Book Value per Share (Most Recent Fiscal Quarter) $4.68
Earnings per Share (Most Recent Fiscal Quarter) $0.04
Earnings per Share (Most Recent Fiscal Year) $0.18
Diluted Earnings per Share (Trailing 12 Months) $0.19
Stock
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Common Shares Outstanding 102.41M
Free Float 97.22M
Market Capitalization $13.24B
Average Volume (Last 20 Days) 0.83M
Beta (Past 60 Months) 1.04
Percentage Held By Insiders (Latest Annual Proxy Report) 5.07%
Percentage Held By Institutions (Latest 13F Reports) 71.65%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%